ProCE Banner Activity

Current Guideline Management of Patients With Bladder Cancer: Highlights and Answers to Your Frequently Asked Questions

Clinical Thought

Read this commentary with experts’ thoughts and considerations for the management of patients with bladder cancer.

Released: January 22, 2025

Expiration: January 21, 2026

Share

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Supported by a grant from Pfizer Inc. and Astellas.

Astellas

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pfizer Inc.

Partners

Clinical Care Options, LLC

ProCE Banner

Faculty Disclosure

Primary Author

Fed Ghali, MD

Assistant Professor
Division of Urologic Oncology
Department of Urology
Yale Cancer Center
Yale School of Medicine
New Haven, Connecticut

Fed Ghali, MD, has no relevant financial relationships to disclose.

Tian Zhang, MD, MHS

Associate Professor
Division of Hematology and Oncology
Department of Internal Medicine
Associate Director of Clinical Research
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, Texas

Tian Zhang, MD, MS: researcher: ALX Oncology, Astellas, AstraZeneca, Bayer, Exelixis, Janssen, Janux, Lilly, Merck, Novartis, OncoC4, Pfizer, Tempus; consultant/advisor: Amgen, Aptitude Health, Aravive, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Caris, Dendreon, Eisai, EMD Serono, Exelixis, Gilead, Janssen, Lilly, Merck, Novartis, Pfizer, Pharmacyclics, QED Therapeutics, SeaGen, Sanofi Aventis, Vaniam, Xencor.